1,068 results on '"DILI"'
Search Results
2. Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System
- Author
-
Makunts, Tigran and Abagyan, Ruben
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,Patient Safety ,Digestive Diseases ,Liver Disease ,DILI ,MDMA ,DDI ,FAERS ,adverse events ,Clinical Sciences ,Public Health and Health Services ,Psychology ,Clinical sciences - Abstract
3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine. It is also metabolized to a lesser extent by CYP1A2, CYP2B6, and CYP3A4 to its active metabolite, 3,4-methylenedioxyamphetamine. Considering the extensive hepatic metabolism and excretion, MDMA use in psychiatry raises concerns over drug-induced liver injury (DILI), a rare but dangerous event. Majority of the drugs withdrawn from the market for liver injury caused death or transplantation at frequencies under 0.01%. Unfortunately, markers for liver injury were not measured in most published clinical trials. At the same time, no visible DILI-related symptoms and adverse events were observed. Idiosyncratic DILI cases are rarely registered during clinical trials due to their rare nature. In this study, we surveyed a larger, over 1,500, and a more diverse set of reports from the FDA Adverse Event Reporting System and found 23 cases of hepatic injury and hepatic failure, in which MDMA was reported to be taken in addition to one or more substances. Interestingly, 22 out of 23 cases had one or more listed drugs with a known DILI concern based on the FDA's DILIrank dataset. Furthermore, only one report had MDMA listed as the primary suspect. Considering the nearly 20 million doses of MDMA used annually, this single report is insufficient for establishing a significant association with DILI.
- Published
- 2024
3. Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review.
- Author
-
Eadie, Lauren, Lo, Lindsay A., Boivin, Michael, Deol, Jagpaul K., and MacCallum, Caroline A.
- Subjects
- *
DRUG side effects , *LIVER enzymes , *MEDICAL sciences , *CANNABIDIOL , *LIVER injuries - Abstract
There is increasing evidence that cannabidiol (CBD) use is associated with clinically significant liver enzyme (LE) elevations and drug‐induced liver injury (DILI). The proportion of LE elevations and DILI events reported in the literature meet the Council for International Organizations of Medical Sciences' (CIOMS) classification of a common adverse drug reaction. However, these potential adverse events are unknown to many clinicians and may be overlooked. The increasing use of CBD for both medical and non‐medical use necessitates clear direction in the diagnosis and management of CBD‐associated hepatotoxicity. To our knowledge, no such clinical guidance currently exists. For people presenting with elevated LEs, CBD use should be screened for and be considered in the differential diagnosis. This narrative review will provide clinicians with guidance in the prevention, detection, and management of CBD‐related hepatotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Clinical and biochemical characteristics, and outcome in 33 patients with ceftriaxone-induced liver injury.
- Author
-
Feng, Cai-Xia, Ye, Wen-Yu, and Shan, Qing-Wen
- Subjects
- *
HEPATOTOXICOLOGY , *KIDNEY failure , *MEDICAL information storage & retrieval systems , *PATIENT safety , *RESEARCH funding , *SICKLE cell anemia , *HEPATITIS , *T-test (Statistics) , *ASPARTATE aminotransferase , *FISHER exact test , *FATIGUE (Physiology) , *JAUNDICE , *SYMPTOMS , *SEVERITY of illness index , *ALKALINE phosphatase , *BILIRUBIN , *DESCRIPTIVE statistics , *MANN Whitney U Test , *CHI-squared test , *AGE distribution , *LIVER diseases , *ITCHING , *SERUM , *SYSTEMATIC reviews , *MEDLINE , *ALANINE aminotransferase , *HEMOLYSIS & hemolysins , *DATA analysis software , *ONLINE information services , *CEFTRIAXONE , *BIOMARKERS , *CHOLESTASIS , *DISEASE incidence , *CHILDREN ,RISK factors - Abstract
Purpose: To summarize the clinical and biochemical characteristics of patients with ceftriaxone-induced liver injury and guide the selection of safe medication. Methods: Retrieved domestic and foreign databases from inception to October 2023, collected case data conforming to ceftriaxone-induced liver injury, and statistically analyzed the data. Results: A total of 617 articles were retrieved, and 16 articles with 33 cases (10 children, 23 adults) were included. Males represented 60% (18/30), with a male-to-female ratio of 1.5:1. The age of onset ranged from 2 days to 96 years, with 15 of 23 adults (65%) over 55 years old. The time from ceftriaxone use to liver injury fluctuated between 0.5 and 47 days. Only 9 patients (27.3%, 9/33) had clinical symptoms, and the clinical classification was dominated by cholestatic injury (46.2%, 12/26). There was a significant difference in the clinical classification of ceftriaxone-induced liver injury between children and adults (P = 0.0126), with hepatocellular injury predominating in children and cholestatic injury predominating in adults. The severity of liver injury was mainly mild (66.7%, 12/18). Peak values of alanine aminotransferase ranging from 228.5 to 8098 U/L, aspartate aminotransferase ranging from 86.7 to 21575 U/L, alkaline phosphatase ranging from 143 to 2434 U/L, and total bilirubin ranging from 3.35 to 66.1 mg/dL. There was a significant difference in peak values of alkaline phosphatase between children and adults (P = 0.027), with a higher peak value of alkaline phosphatase in adults (1039 ± 716.4 U/L vs. 257 ± 134.9 U/L). Patients with normal imaging examinations accounted for the majority (61.5%, 7/13). The prognosis of 32 patients (97%, 32/33) was good, and one child with sickle cell anemia who developed immune hemolysis, progressive renal failure, and acute liver injury after using ceftriaxone died in the end. Conclusion: Ceftriaxone-induced liver injury can occur at any age, with a higher risk in the elderly, and age may be related to the clinical classification. Although the clinical manifestations are not specific, close monitoring of liver biochemical indicators during the use can detect liver injury early. Most cases have a good prognosis, but for people with concomitant sickle cell anemia, it is necessary to be vigilant about the occurrence of severe hemolytic anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Obliterative Portal Venopathy during Estrogen Therapy in a Transgender Woman: A Case Report.
- Author
-
Ash, Nathaniel S., Schiano, Thomas D., Safer, Joshua D., Fiel, Maria I., Skolnick, Aren H., and Bach, Nancy
- Subjects
LIVER disease diagnosis ,ESTROGEN replacement therapy ,PORTAL vein ,HYPERPLASIA ,ENZYMES ,CHRONIC active hepatitis ,LIVER diseases ,CLINICAL pathology ,HORMONE therapy ,NEEDLE biopsy ,TRANS women - Abstract
Background: As transgender people initiate gender-affirming hormone therapy (GAHT), they are exposed to exogenous sex hormones that have effects that have not yet been fully studied. While exogenous estrogen is associated with a risk of venous thrombosis, the full impact of estrogen on the liver is unknown. Conversely, the erroneous attribution of risks from GAHT presents a barrier to treatment for some patients. We present a case of obliterative portal venopathy (OPV) and possible DILI occurring after the initiation of estrogen in a transgender woman. Case presentation: A 28-year-old transgender woman on GAHT was referred to hepatology for liver enzyme elevations. She did not have any notable comorbid conditions, family history, or psychosocial history. Lab and imaging workup were unremarkable, and the patient underwent liver biopsy. The patient's biopsy results showed OPV. The patient continued GAHT at a lower dose and liver enzyme elevations resolved. Conclusions: OPV is a vascular disease that falls under the category of porto-sinusoidal vascular disorder. Patients with this condition can present with or without overt clinical signs of portal hypertension. Porto-sinusoidal vascular disorder is rare and given the timing and possible dose dependence, it might be reasonable to consider that the observed OPV was influenced by the exogenous estrogen administered in an association not previously reported. Alternatively, the patient's continued estrogen treatment without ill effect could suggest that the events were not connected and that the fear of harm could have served as a barrier to the patient receiving indicated care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Regular Consumption of Green Tea as an Element of Diet Therapy in Drug-Induced Liver Injury (DILI).
- Author
-
Winiarska-Mieczan, Anna, Jachimowicz-Rogowska, Karolina, Kwiecień, Małgorzata, Borsuk-Stanulewicz, Marta, Tomczyk-Warunek, Agnieszka, Stamirowska-Krzaczek, Ewa, Purwin, Cezary, Stryjecka, Małgorzata, and Tomaszewska, Marzena
- Abstract
The liver is a highly metabolically active organ, and one of the causes of its dysfunction is the damage caused by drugs and their metabolites as well as dietary supplements and herbal preparations. A common feature of such damage is drugs, which allows it to be defined as drug-induced liver injury (DILI). In this review, we analysed available research findings in the global literature regarding the effects of green tea and/or its phenolic compounds on liver function in the context of protective action during prolonged exposure to xenobiotics. We focused on the direct detoxifying action of epigallocatechin gallate (EGCG) in the liver, the impact of EGCG on gut microbiota, and the influence of microbiota on liver health. We used 127 scientific research publications published between 2014 and 2024. Improving the effectiveness of DILI detection is essential to enhance the safety of patients at risk of liver damage and to develop methods for assessing the potential hepatotoxicity of a drug during the research phase. Often, drugs cannot be eliminated, but appropriate nutrition can strengthen the body and liver, which may mitigate adverse changes resulting from DILI. Polyphenols are promising owing to their strong antioxidant and anti-inflammatory properties as well as their prebiotic effects. Notably, EGCG is found in green tea. The results of the studies presented by various authors are very promising, although not without uncertainties. Therefore, future research should focus on elucidating the therapeutic and preventive mechanisms of polyphenols in the context of liver health through the functioning of gut microbiota affecting overall health, with particular emphasis on epigenetic pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Difficulty in differentiating liver injury from an immune checkpoint inhibitor from chemotherapy.
- Author
-
Shike Lou, Xiaoyin Wang, Fei Yuan, Gangde Zhao, Mingyang Feng, Yezhou Ding, Lanyi Lin, Kehui Liu, Xiaolin Wang, Wanqing Chi, and Hui Wang
- Subjects
IMMUNE checkpoint inhibitors ,PEMETREXED ,LIVER biopsy ,COMBINATION drug therapy ,MEDICAL personnel ,LUNGS - Abstract
This study investigated the potential of immune checkpoint inhibitors (ICIs) combined with chemotherapy as a promising treatment approach for malignancies. This report focuses on a patient with drug-induced liver injury (DILI) following the administration of chemotherapy and ICIs. A 63-year-old patient with non-small cell lung adenocarcinoma (NSCLC) initially underwent γ-knife treatment and subsequently received a combination of chemotherapy comprising bevacizumab and camrelizumab. Due to liver abnormalities, both chemotherapy and ICIs were stopped on day 21. The patient's liver function improved within a month after methylprednisolone treatment. Subsequently, the patient received carboplatin, pemetrexed, and bevacizumab without complications. This finding supported the notion that DILI was likely triggered by the ICI. This case series details a complex instance of DILI resulting from the use of ICIs and pemetrexed/carboplatin. The alignment of the pathological findings and clinical presentation strongly suggested ICI-induced DILI, which was further supported by the definitive response to steroid treatment. This information is important for clinicians, as it emphasizes the importance of closely monitoring liver function and being aware of potential adverse effects associated with ICIs. Such insights contribute to more effective patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS).
- Author
-
He, Sidi, Chen, Bin, and Li, Chuanwei
- Subjects
DRUG side effects ,LIVER enzymes ,ODDS ratio ,DATABASES ,HEPATOTOXICOLOGY ,AMISULPRIDE ,ARIPIPRAZOLE - Abstract
Background: Recent studies have shown that liver enzyme abnormalities were not only seen with typical antipsychotics (APs) but also with atypical antipsychotics (AAPs). During the last 20 years, the hepatotoxicity of various antipsychotics received much attention. However, systematic evaluations of hepatotoxicity associated with APs are limited. Methods: All drug related hepatic disorders cases were retrieved from the FDA Adverse Event Reporting System (FAERS) database using standardized MedDRA queries (SMQ) from the first quarter of 2017 to the first quarter of 2022. Patient characteristics and prognosis were assessed. In this study, a case/non-case approach was used to calculate reporting odds ratio (RORs) and 95% confidence intervals (CIs). We calculated the drug-induced liver injury (DILI) RORs for each AAPs. Results: A total of 408 DILI cases were attributed to AAPs during the study period. 18.6% of these were designated as serious adverse event (SAE), which include death (19.74%), hospitalization (68.42%), disability (2.63%), and life-threatening (9.21%) outcomes. The RORs values in descending order were: quetiapine (ROR = 0.782), clozapine (ROR = 0.665), aripiprazole (ROR = 0.507), amisulpride (ROR = 0.308), paliperidone (ROR = 0.212), risperidone (ROR = 0.198), ziprasidone (0.131). Conclusion: The result found in our study was that all AAPs didn't have a significant correlation with increased hepatotoxicity. Future analysis of the FAERS database in conjunction with other data sources will be essential for continuous monitoring of DILI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Drug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals.
- Author
-
Buron, Nelly, Porceddu, Mathieu, Loyant, Roxane, Martel, Cécile, Allard, Julien A, Fromenty, Bernard, and Borgne-Sanchez, Annie
- Subjects
- *
LIVER mitochondria , *FATTY acid oxidation , *MEMBRANE potential , *REACTIVE oxygen species , *DRUG side effects - Abstract
Drug-induced liver injury (DILI) represents a major issue for pharmaceutical companies, being a potential cause of black-box warnings on marketed pharmaceuticals, or drug withdrawal from the market. Lipid accumulation in the liver also referred to as steatosis, may be secondary to impaired mitochondrial fatty acid oxidation (mtFAO). However, an overall causal relationship between drug-induced mtFAO inhibition and the occurrence of steatosis in patients has not yet been established with a high number of pharmaceuticals. Hence, 32 steatogenic and 13 nonsteatogenic drugs were tested for their ability to inhibit mtFAO in isolated mouse liver mitochondria. To this end, mitochondrial respiration was measured with palmitoyl- l -carnitine, palmitoyl-CoA + l -carnitine, or octanoyl- l -carnitine. This mtFAO tri-parametric assay was able to predict the occurrence of steatosis in patients with a sensitivity and positive predictive value above 88%. To get further information regarding the mechanism of drug-induced mtFAO impairment, mitochondrial respiration was also measured with malate/glutamate or succinate. Drugs such as diclofenac, methotrexate, and troglitazone could inhibit mtFAO secondary to an impairment of the mitochondrial respiratory chain, whereas dexamethasone, olanzapine, and zidovudine appeared to impair mtFAO directly. Mitochondrial swelling, transmembrane potential, and production of reactive oxygen species were also assessed for all compounds. Only the steatogenic drugs amiodarone, ketoconazole, lovastatin, and toremifene altered all these 3 mitochondrial parameters. In conclusion, our tri-parametric mtFAO assay could be useful in predicting the occurrence of steatosis in patients. The combination of this assay with other mitochondrial parameters could also help to better understand the mechanism of drug-induced mtFAO inhibition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential
- Author
-
Benet, Leslie Z
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Orphan Drug ,Rare Diseases ,Humans ,Solubility ,Permeability ,Biopharmaceutics ,Chemical and Drug Induced Liver Injury ,Brain ,Pharmaceutical Preparations ,Permeability rate ,BDDCS ,ECCS ,BCS ,Food effects ,Brain penetration ,DILI ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
Here I detail the use of measures of permeability rate and solubility in predicting drug disposition characteristics through the utilization of the Biopharmaceutics Drug Disposition Classification System (BDDCS) and the Extended Clearance Classification System (ECCS) as well as the accuracy of the systems in predicting the major route of elimination and the extent of oral absorption of a new small molecule therapeutics. I compare the BDDCS and ECCS with the FDA Biopharmaceutics Classification System (BCS). I also detail the use of the BCS in predicting food effects and the BDDCS in predicting brain disposition of small molecule therapeutics and in validating DILI predictive metrics. This review provides an update of the current status of these classification systems and their uses in the drug development process.
- Published
- 2023
11. The role of exosomal lncRNAs in acetaminophen-induced induced liver injury in SD rats
- Author
-
Zixuan Yang, Lei Shi, Minhui Zheng, Minbo Hou, Mengdi Zhou, Naying Su, Hui Lang, Liyuan Zhao, Mengyun Gu, Naping Tang, and Yan Chang
- Subjects
Exosome ,LncRNA ,RNA sequencing ,PCR ,DILI ,Genetics ,QH426-470 - Abstract
Background: Drug-induced liver injury (DILI) is a leading cause of drug development failures during clinical trials and post-market introduction. Current biomarkers, such as ALT and AST, lack the necessary specificity and sensitivity needed for accurate detection. Exosomes, which protect LncRNAs from RNase degradation, could provide reliable and easily accessible options for biomarkers. Materials and methods: RNA-sequencing was used to identify differentially expressed LncRNAs (DE-LncRNAs), followed by isolation of LncRNAs from plasma exosomes in this study. Exosome characterization was conducted by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and Western blot (WB). Bioinformatics analysis included functional enrichment and co-expression network analysis. Five rat models were established, and quantitative real-time PCR was used to verify the specificity and sensitivity of two candidate exosomal LncRNAs. Results: The APAP-induced hepatocellular injury model was successfully established for RNA-sequencing, leading to the identification of several differentially expressed exosomal LncRNAs. Eight upregulated exosomal DE-LncRNAs were selected for validation. Among them, NONRATT018001.2 (p
- Published
- 2024
- Full Text
- View/download PDF
12. Obliterative Portal Venopathy during Estrogen Therapy in a Transgender Woman: A Case Report
- Author
-
Nathaniel S. Ash, Thomas D. Schiano, Joshua D. Safer, Maria I. Fiel, Aren H. Skolnick, and Nancy Bach
- Subjects
DILI ,gender-affirming hormone therapy ,Medicine (General) ,R5-920 - Abstract
Background: As transgender people initiate gender-affirming hormone therapy (GAHT), they are exposed to exogenous sex hormones that have effects that have not yet been fully studied. While exogenous estrogen is associated with a risk of venous thrombosis, the full impact of estrogen on the liver is unknown. Conversely, the erroneous attribution of risks from GAHT presents a barrier to treatment for some patients. We present a case of obliterative portal venopathy (OPV) and possible DILI occurring after the initiation of estrogen in a transgender woman. Case presentation: A 28-year-old transgender woman on GAHT was referred to hepatology for liver enzyme elevations. She did not have any notable comorbid conditions, family history, or psychosocial history. Lab and imaging workup were unremarkable, and the patient underwent liver biopsy. The patient’s biopsy results showed OPV. The patient continued GAHT at a lower dose and liver enzyme elevations resolved. Conclusions: OPV is a vascular disease that falls under the category of porto-sinusoidal vascular disorder. Patients with this condition can present with or without overt clinical signs of portal hypertension. Porto-sinusoidal vascular disorder is rare and given the timing and possible dose dependence, it might be reasonable to consider that the observed OPV was influenced by the exogenous estrogen administered in an association not previously reported. Alternatively, the patient’s continued estrogen treatment without ill effect could suggest that the events were not connected and that the fear of harm could have served as a barrier to the patient receiving indicated care.
- Published
- 2024
- Full Text
- View/download PDF
13. Antibiotic-Associated Drug-Induced Liver Injury in Critically Ill Children: A Prospective Observational Study
- Author
-
A. V. Vlasova, Yu. F. Shubina, and D. A. Sychev
- Subjects
paediatrics ,antibiotics ,drug-induced liver diseases ,dili ,hepatotoxicity ,cholestatic hepatitis ,adverse drug reactions ,global trigger tool ,clinical trial ,Therapeutics. Pharmacology ,RM1-950 - Abstract
INTRODUCTION. Drug-induced liver injury (DILI) is associated, among other things, with the use of antibiotics. Children with DILI are at risk of acute liver failure and even death. However, the literature on the subject provides little information on the possibility of distinguishing the types of hepatic lesions to diagnose potentially life-threatening DILI in time.AIM. The study aimed to describe the phenotype of new-onset DILI associated with antibiotics in critically ill children with nosocomial infection.MATERIALS AND METHODS. The authors conducted a prospective observational study in the resuscitation and intensive care units of the Morozov Children’s City Clinical Hospital from 1 February 2020 to 1 September 2021. The study assessed the incidence of antibiotic-associated DILI using the Global Trigger Tool. The study enrolled 100 critically ill children aged 0 to 17 years (44 boys and 56 girls) with nosocomial infection.RESULTS. Signs of hepatotoxicity were detected in 19 patients, including 8 with abnormal liver function tests but normal liver function and 11 with abnormal liver function tests and clinically apparent liver disease. Thus, the incidence of new-onset hepatotoxicity associated with antibiotics amounted to 12.9 cases per 100,000 paediatric patients, and the incidence of DILI was 7.5 cases per 100,000 children. Based on the analysis of medical records, biochemical findings, and relationships between the time of dosing and the manifestation of signs of liver disorder in 11 children, the authors characterised the phenotype of idiosyncratic cholestatic hepatitis. Critically ill children treated with antibiotics showed alanine transaminase activity up to 10 times the upper limit of normal (ULN), bilirubin levels up to 4.45 times the ULN, and gamma-glutamyl transferase activity up to 5 times the ULN. The odds of developing new-onset DILI were the highest with tigecycline (OR: 4.07; 95% CI: 1.32–12.50) and meropenem (OR: 1.84; 95% CI: 1.01–3.36). In 6 patients, clinical signs of idiosyncratic cholestatic hepatitis resolved within a few weeks after antibiotic discontinuation. The other 5 patients with clinical signs of idiosyncratic cholestatic hepatitis died.CONCLUSIONS. The authors described the phenotype of idiosyncratic cholestatic liver injury associated with antibiotics in critically ill children. The role of pharmacogenetic markers in the development of DILI associated with antibiotics in critically ill children needs to be assessed further to implement a risk-based approach and mitigate the risks.The study was registered at ClinicalTrials.gov under No. NCT04141657 on 24 October 2019.
- Published
- 2024
- Full Text
- View/download PDF
14. Cytokeratin-18 is a sensitive biomarker of alanine transaminase increase in a placebo-controlled, randomized, crossover trial of therapeutic paracetamol dosing (PATH-BP biomarker substudy).
- Author
-
Scullion, Kathleen M, MacIntyre, Iain M, Sloan-Dennison, Sian, Clark, Benjamin, Fineran, Paul, Mair, Joanne, Creasey, David, Rathmell, Cicely, Faulds, Karen, Graham, Duncan, Webb, David J, and Dear, James W
- Subjects
- *
ALANINE aminotransferase , *CROSSOVER trials , *GLUTAMATE dehydrogenase , *ACETAMINOPHEN , *BIOMARKERS , *FLUTICASONE - Abstract
Drug-induced liver injury (DILI) is a challenge in clinical medicine and drug development. Highly sensitive novel biomarkers have been identified for detecting DILI following a paracetamol overdose. The study objective was to evaluate biomarker performance in a 14-day trial of therapeutic dose paracetamol. The PATH-BP trial was a double-blind, placebo-controlled, crossover study. Individuals (n = 110) were randomized to receive 1 g paracetamol 4× daily or matched placebo for 2 weeks followed by a 2-week washout before crossing over to the alternate treatment. Blood was collected on days 0 (baseline), 4, 7, and 14 in both arms. Alanine transaminase (ALT) activity was measured in all patients. MicroRNA-122 (miR-122), cytokeratin-18 (K18), and glutamate dehydrogenase (GLDH) were measured in patients who had an elevated ALT on paracetamol treatment (≥50% from baseline). ALT increased in 49 individuals (45%). All 3 biomarkers were increased at the time of peak ALT (K18 paracetamol arm: 18.9 ± 9.7 ng/ml, placebo arm: 11.1 ± 5.4 ng/ml, ROC-AUC = 0.80, 95% CI 0.71–0.89; miR-122: 15.1 ± 12.9fM V 4.9 ± 4.7fM, ROC-AUC = 0.83, 0.75–0.91; and GLDH: 24.6 ± 31.1U/l V 12.0 ± 11.8U/l, ROC-AUC = 0.66, 0.49–0.83). All biomarkers were correlated with ALT (K18 r = 0.68, miR-122 r = 0.67, GLDH r = 0.60). To assess sensitivity, biomarker performance was analyzed on the visit preceding peak ALT (mean 3 days earlier). K18 identified the subsequent ALT increase (K18 ROC-AUC = 0.70, 0.59–0.80; miR-122 ROC-AUC = 0.60, 0.49–0.72, ALT ROC-AUC = 0.59, 0.48–0.70; GLDH ROC-AUC = 0.70, 0.50–0.90). Variability was lowest for ALT and K18. In conclusion, K18 was more sensitive than ALT, miR-122, or GLDH and has potential significant utility in the early identification of DILI in trials and clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Spatial Computational Hepatic Molecular Biomarker Reveals LSEC Role in Midlobular Liver Zonation Fibrosis in DILI and NASH Liver Injury.
- Author
-
Puri, Munish
- Subjects
- *
HEPATIC fibrosis , *LIVER injuries , *BIOMARKERS , *LIVER cells , *TRANSCRIPTOMES - Abstract
The liver is structurally organized into zonation, where Liver Sinusoidal Endothelial Cells (LSECs) play a crucial role during chronic liver injury and the early stages of fibrosis. Fibrosis can be reversed if diagnosed early at the molecular level in zonation before progressing to advanced stages like bridging fibrosis. This study identified zonation marker genes using scRNA-seq and spatial transcriptomics molecular profiling technologies in a normal and diseased fibrotic human liver. DGE analysis was performed over LSECs, and we identified the top 20 expressed genes in the periportal, perivenous, and intermediate acinar zones. Multi-omics and scRNA-seq analysis over Visium images and ECs liver cells showed OIT3, DNASE1L3, CLEC4G, LYVE1, FCN2, and CRHBP as commonly expressed mid-lobular zonation-specific genes. Also, this study detected STAB2, F8, AQP1, TEK, TIMP3, TIE1, and CTSL genes as expressed in DILI and NASH EC populations. The connection between LSEC marker genes in zone 2 and liver fibrosis holds significant promise for advancing our understanding in developing new therapeutic strategies for fibrosis reversal and designing computational molecular biomarkers in NASH and DILI fibrotic liver diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Exploring Acute Liver Damage: Slimming Health Foods and CYP3A4 Induction.
- Author
-
Makiko Adachi, Takeshi Kumagai, Keiko Hosho, Kiyoshi Nagata, Masachika Fujiyoshi, and Miki Shimada
- Subjects
CYTOCHROME P-450 ,HEPATITIS treatment ,ACETAMINOPHEN ,DRUG metabolism ,FOOD consumption - Abstract
Background: Patients taking multiple drugs and various health foods often develop acute hepatitis. We hypothesized that the interaction between health foods and drug metabolism was the cause of severe liver injury in these patients. Therefore, we studied changes in the activity of the drug-metabolizing enzyme, cytochrome P450 (CYP), using slimming health food extracts and elucidated the molecular mechanism of liver injury onset through hepatotoxicity evaluation. Methods For cytotoxicity testing, health food extract samples were added to HepG2 cells derived from hepatic parenchymal cells and culture medium, and cell viability was calculated 48 h after culture. To evaluate CYP3A4 induction, 3-1-10 cells constructed with a reporter linked to CYP3A4 gene were used, and reporter activity was measured 48 h after culture. Results: In the chronological order of the slimming health food intake history of the patient, niacinamide and Gymnema sylvestre extracts strongly inhibited HepG2 cell viability. In contrast, dietary supplements A and Coleus forskohlii extract strongly induced CYP3A4 reporter activity. To confirm CYP3A4 induction in humans, humanized CYP3A/pregnane X receptor (PXR) mice were treated with forskolin. CYP3A4 mRNA expression levels were elevated 3.9 times compared to that of the control group (P < 0.05). Conclusion: Coleus forskohlii extract showed the strongest transcriptional activation of CYP3A4 gene. In a mouse model of human-type drug metabolism, forskolin induced CYP3A4 transcription. Thus, we concluded that CYP3A4 induction by Coleus forskohlii is one of the causes of crucial hepatocellular injury, which is a type of liver injury caused by the active metabolite of acetaminophen produced by CYP3A4. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury.
- Author
-
Alés-Palmer, María Luisa, Andújar-Vera, Francisco, Iglesias-Baena, Iván, Muñoz-de-Rueda, Paloma, and Ocete-Hita, Esther
- Subjects
GENETIC variation ,LIVER injuries ,DRUG side effects ,CHILD patients ,EXOMES ,BLOOD coagulation factor XIII ,DRUG metabolism - Abstract
Idiosyncratic drug-induced liver injury (DILI) is a complex multifactorial disease in which the toxic potential of the drug, together with genetic and acquired factors and deficiencies in adaptive processes, which limit the extent of damage, may determine susceptibility and make individuals unique in their development of hepatotoxicity. In our study, we sequenced the exomes of 43 pediatric patients diagnosed with DILI to identify important gene variations associated with this pathology. The result showed the presence of two variations in the NAT2 gene: c.590G>A (p.Arg197Gln) and c.341T>C (p.Ile114Thr). These variations could be found separately or together in 41 of the 43 patients studied. The presence of these variations as a risk factor for DILI could confirm the importance of the acetylation pathway in drug metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment.
- Author
-
Ma, J., Björnsson, E. S., and Chalasani, N.
- Subjects
- *
ANTIFUNGAL agents , *HEPATOTOXICOLOGY , *DRUG labeling , *DRUG side effects , *ANTIBIOTICS - Abstract
Idiosyncratic drug-induced liver injury (DILI) is a rare and unpredictable form of hepatotoxicity. While its clinical course is usually benign, cases leading to liver transplantation or death can occur. Based on modern prospective registries, antimicrobials including antibiotics and antifungals are frequently implicated as common causes. Amoxicillin–clavulanate ranks as the most common cause for DILI in the Western World. Although the absolute risk of hepatotoxicity of these agents is low, as their usage is quite high, it is not uncommon for practitioners to encounter liver injury following the initiation of antibiotic or antifungal therapy. In this review article, mechanisms of hepatoxicity are presented. The adverse hepatic effects of well-established antibiotic and antifungal agents are described, including their frequency, severity, and pattern of injury and their HLA risks. We also review the drug labeling and prescription guidance from regulatory bodies, with a focus on individuals with hepatic impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS).
- Author
-
Shi, Alan, Nguyen, Harold, Kuo, C. Benson, and Beringer, Paul M.
- Subjects
- *
LIVER injuries , *DRUG side effects , *LIVER function tests , *CYSTIC fibrosis , *DATA mining , *ISCHEMIC colitis , *INVASIVE candidiasis - Abstract
• Using the FDA adverse event reporting system database, ETI and DILI reports were found to be significantly associated (p < 0.05) for all disproportionality measures (PRR, ROR, IC, EGBM, chi-squared). • The ROR for ETI-DILI is greater than that of ∼10 % of the "Most-DILI concern" drugs in the FDA DILIRank dataset. • ETI-DILI reports for people with cystic fibrosis were predominately male, in contrast to patient reports for other drugs and DILI. • "Hospitalization" was the second most common patient outcome for ETI-DILI after "other serious outcomes". • Most people with cystic fibrosis experienced onset times within 3 months of initiation; however, several occurred prior to 3 months or beyond 1 year, indicating additional monitoring may be prudent. The efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ETI) have been established in prospective clinical trials. Liver function test elevations were observed in a greater proportion of patients receiving ETI compared with placebo; however, the relatively small number of patients and short duration of study preclude detection of rare but clinically significant associations with drug-induced liver injury (DILI). To address this gap, we assessed the real-world risk of DILI associated with ETI through data mining of the FDA adverse event reporting system (FAERS). Disproportionality analyses were conducted on FAERS data from the fourth quarter of 2019 through the third quarter of 2022. Comparative patient demographics, onset time and outcomes for ETI-DILI were also obtained. 452 reports of DILI associated with ETI were found, representing 2.1 % of all adverse event reports for ETI. All disproportionality measures were significant for ETI-DILI at p < 0.05; the reporting odds ratio (ROR) (2.82) was comparable to that of drugs classified by FDA as "Most-DILI concern". The most notable demographic finding was a male majority (5:4 male to female ratio) for ETI-DILI compared to a female majority (4:5 male to female ratio) for non ETI-DILI. Median ETI-DILI onset time was 50.5 days, and hospitalization was the second most common complication. Using FAERS data, ETI was found to be disproportionately associated with DILI. Future research is needed to investigate the hepatotoxic mechanisms and assess potential mitigation strategies for ETI-induced hepatotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Liver-on-chips for drug discovery and development
- Author
-
Viraj Mehta, Guruswamy Karnam, and Vamsi Madgula
- Subjects
Liver-on-chips ,Liver organoids ,Liver spheroids ,Hepatic clearance ,DILI ,Microphysiological systems ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Recent FDA modernization act 2.0 has led to increasing industrial R&D investment in advanced in vitro 3D models such as organoids, spheroids, organ-on-chips, 3D bioprinting, and in silico approaches. Liver-related advanced in vitro models remain the prime area of interest, as liver plays a central role in drug clearance of compounds. Growing evidence indicates the importance of recapitulating the overall liver microenvironment to enhance hepatocyte maturity and culture longevity using liver-on-chips (LoC) in vitro. Hence, pharmaceutical industries have started exploring LoC assays in the two of the most challenging areas: accurate in vitro-in vivo extrapolation (IVIVE) of hepatic drug clearance and drug-induced liver injury. We examine the joint efforts of commercial chip manufacturers and pharmaceutical companies to present an up-to-date overview of the adoption of LoC technology in the drug discovery. Further, several roadblocks are identified to the rapid adoption of LoC assays in the current drug development framework. Finally, we discuss some of the underexplored application areas of LoC models, where conventional 2D hepatic models are deemed unsuitable. These include clearance prediction of metabolically stable compounds, immune-mediated drug-induced liver injury (DILI) predictions, bioavailability prediction with gut-liver systems, hepatic clearance prediction of drugs given during pregnancy, and dose adjustment studies in disease conditions. We conclude the review by discussing the importance of PBPK modeling with LoC, digital twins, and AI/ML integration with LoC.
- Published
- 2024
- Full Text
- View/download PDF
21. Damage Detection of Span Bridge Structures Under Moving Loads Using the Hybrid Enhanced SOS-SA Algorithm
- Author
-
Makiabadi, Mohammad H., Maheri, Mahmoud R., and Sarcheshmehpour, M.
- Published
- 2024
- Full Text
- View/download PDF
22. Spatial Computational Hepatic Molecular Biomarker Reveals LSEC Role in Midlobular Liver Zonation Fibrosis in DILI and NASH Liver Injury
- Author
-
Munish Puri
- Subjects
NASH ,DILI ,LSEC ,DGE ,liver zonation marker ,bridging fibrosis ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
The liver is structurally organized into zonation, where Liver Sinusoidal Endothelial Cells (LSECs) play a crucial role during chronic liver injury and the early stages of fibrosis. Fibrosis can be reversed if diagnosed early at the molecular level in zonation before progressing to advanced stages like bridging fibrosis. This study identified zonation marker genes using scRNA-seq and spatial transcriptomics molecular profiling technologies in a normal and diseased fibrotic human liver. DGE analysis was performed over LSECs, and we identified the top 20 expressed genes in the periportal, perivenous, and intermediate acinar zones. Multi-omics and scRNA-seq analysis over Visium images and ECs liver cells showed OIT3, DNASE1L3, CLEC4G, LYVE1, FCN2, and CRHBP as commonly expressed mid-lobular zonation-specific genes. Also, this study detected STAB2, F8, AQP1, TEK, TIMP3, TIE1, and CTSL genes as expressed in DILI and NASH EC populations. The connection between LSEC marker genes in zone 2 and liver fibrosis holds significant promise for advancing our understanding in developing new therapeutic strategies for fibrosis reversal and designing computational molecular biomarkers in NASH and DILI fibrotic liver diseases.
- Published
- 2024
- Full Text
- View/download PDF
23. Herbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature
- Author
-
Palak A. Patel-Rodrigues, Lindsey Cundra, Dalal Alhaqqan, Daniel T. Gildea, Stephanie M. Woo, and James H. Lewis
- Subjects
HILI ,herbal-induced liver injury ,dietary supplement and liver injury ,DILI ,herbal supplementation and liver injury ,herbal and dietary supplement (HDS)-induced liver injury ,Medicine (General) ,R5-920 - Abstract
Herbal-induced liver injury (HILI) continues to increase in prevalence each year due to the ongoing popularity of herbal supplements and complementary and alternative medicines. A detailed literature review of case reports and clinical studies published from March 2021 to March 2023 was performed. We discuss the epidemiology and diagnosis of HILI as well as the current and proposed laws and regulations. The 2021 ACG guidelines and 2022 AASLD practice guidelines for the diagnosis and management of drug and herbal-induced liver injury are discussed. We describe updates to previously reported etiologies of HILI such as ayurveda, ashwagandha, turmeric, kratom, green tea extract, and garcinia cambogia. Newly described supplements resulting in HILI, such as tinospora cordifolia, horse chestnut, alkaline water, and more, are described. We discuss newly and previously identified hepatoprotective herbal supplements as they have been reported in the study of animal models and human liver cells. This review suggests the need for ongoing research on the causes and mechanisms of HILI to ensure its proper diagnosis, prevention, and treatment in the future. The goal of this review is to provide novice and expert readers with knowledge regarding the possible etiologies of HILI and a general overview.
- Published
- 2024
- Full Text
- View/download PDF
24. Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice
- Author
-
Shenhai Gong, Yunong Zeng, Ze Wang, Yanru Li, Rong Wu, Lei Li, Hongbin Hu, Ping Qin, Zhichao Yu, Xintao Huang, Peiheng Guo, Hong Yang, Yi He, Zhibin Zhao, Weidong Xiao, Xiaoshan Zhao, Lei Gao, Shumin Cai, and Zhenhua Zeng
- Subjects
DILI ,gut microbiota ,gender variability ,deguelin ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Acetaminophen (APAP) overdose is a leading cause of drug-induced liver injury (DILI), with gender-specific differences in susceptibility. However, the mechanism underlying this phenomenon remains unclear. Our study reveals that the gender-specific differences in susceptibility to APAP-induced hepatotoxicity are due to differences in the gut microbiota. Through microbial multi-omics and cultivation, we observed increased gut microbiota-derived deguelin content in both women and female mice. Administration of deguelin was capable of alleviating hepatotoxicity in APAP-treated male mice, and this protective effect was associated with the inhibition of hepatocyte oxidative stress. Mechanistically, deguelin reduced the expression of thyrotropin receptor (TSHR) in hepatocytes with APAP treatment through direct interaction. Pharmacologic suppression of TSHR expression using ML224 significantly increased hepatic glutathione (GSH) in APAP-treated male mice. These findings suggest that gut microbiota-derived deguelin plays a crucial role in reducing APAP-induced hepatotoxicity in female mice, offering new insights into therapeutic strategies for DILI.
- Published
- 2024
- Full Text
- View/download PDF
25. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
- Author
-
Kawano, Miki, Yano, Yoshihiko, Yamamoto, Atsushi, Yasutomi, Eiichiro, Inoue, Yuta, Kitadai, Jun, Yoshida, Ryutaro, Matsuura, Takanori, Shiomi, Yuuki, Ueda, Yoshihide, and Kodama, Yuzo
- Subjects
- *
IMMUNE checkpoint proteins , *LIVER biopsy , *LIVER injuries , *IMMUNE checkpoint inhibitors , *LYMPHOCYTE count - Abstract
Immune checkpoint inhibitor (ICI)-induced liver injury (LI) is a common adverse event, but the clinical characteristics based on the classification of hepatocellular injury and cholestatic types are not fully evaluated. This study aims to analyze risk factors and histological findings in relation to the classification of ICI-induced LI. In total, 254 ICI-induced LI patients among 1086 treated with ICIs between September 2014 and March 2022 were classified according to the diagnostic criteria for drug-induced LI (DILI), and their risk factors and outcomes were evaluated. Kaplan–Meier analyses showed that overall survival in patients with hepatocellular-injury-type LI was significantly longer than others (p < 0.05). Regarding pre-treatment factors, the lymphocyte count was significantly higher in patients with ICI-induced LI, especially in hepatocellular-injury-type LI. Gamma glutamyl transferase (γGTP) and alkaline phosphatase (ALP) were also significantly lower in patients with ICI-induced LI (p < 0.05). Multivariate analyses revealed that malignant melanoma, high lymphocyte count, and low ALP levels were extracted as factors contributing to hepatocellular-injury-type LI. The histological findings among 37 patients diagnosed as ICI-induced LI via liver biopsy also revealed that the spotty/focal necrosis was significantly frequent in hepatocellular-injury-type LI, whereas ductular reactions were frequently observed in cholestatic-type LI. It is suggested that the histological inflammation pattern in patients with LI is closely correlated with the type of DILI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.
- Author
-
Teschke, Rolf and Danan, Gaby
- Subjects
LIVER injuries ,GENETICS ,DRUG side effects ,LEUCOCYTES ,INJURY risk factors - Abstract
The human leucocyte antigen (HLA) allele variability was studied in cohorts of patients with idiosyncratic drug-induced liver injury (iDILI). Some reports showed an association between HLA genetics and iDILI, proposing HLA alleles as a potential risk factor for the liver injury. However, the strength of such assumptions heavily depends on the quality of the iDILI diagnosis, calling for a thorough analysis. Using the PubMed database and Google Science, a total of 25 reports of case series or single cases were retrieved using the terms HLA genes and iDILI. It turned out that in 10/25 reports (40%), HLA genetics were determined in iDILI cases, for which no causality assessment method (CAM) was used or a non-validated tool was applied, meaning the findings were based on subjective opinion, providing disputable results and hence not scoring individual key elements. By contrast, in most iDILI reports (60%), the Roussel Uclaf Causality Assessment Method (RUCAM) was applied, which is the diagnostic algorithm preferred worldwide to assess causality in iDILI cases and represents a quantitative, objective tool that has been well validated by both internal and external DILI experts. The RUCAM provided evidence-based results concerning liver injury by 1 drug class (antituberculotics + antiretrovirals) and 19 different drugs, comprising 900 iDILI cases. Among the top-ranking drugs were amoxicillin–clavulanate (290 cases, HLA A*02:01 or HLA A*30:02), followed by flucloxacillin (255 cases, HLA B*57:01), trimethoprim–sulfamethoxazole (86 cases, HLA B*14:01 or HLA B*14:02), methimazole (40 cases, HLA C*03:02), carbamazepine (29 cases, HLA A*31:01), and nitrofurantoin (26 cases, HLA A*33:01). In conclusion, the HLA genetics in 900 idiosyncratic drug-induced liver injury cases with evidence based on the RUCAM are available for studying the mechanistic steps leading to the injury, including metabolic factors through cytochrome P450 isoforms and processes that activate the innate immune system to the adaptive immune system. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Exploring Individual Variability in Drug-Induced Liver Injury (DILI) Responses through Metabolomic Analysis.
- Author
-
Moreno-Torres, Marta, Quintás, Guillermo, Martínez-Sena, Teresa, Jover, Ramiro, and Castell, José V.
- Subjects
- *
LIVER injuries , *DRUG side effects , *METABOLOMICS , *ALKALINE phosphatase , *ALANINE aminotransferase , *BILE acids - Abstract
Drug-induced liver injury (DILI) is a serious adverse hepatic event presenting diagnostic and prognostic challenges. The clinical categorization of DILI into hepatocellular, cholestatic, or mixed phenotype is based on serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) values; however, this classification may not capture the full spectrum of DILI subtypes. With this aim, we explored the utility of assessing changes in the plasma metabolomic profiles of 79 DILI patients assessed by the RUCAM (Roussel Uclaf Causality Assessment Method) score to better characterize this condition and compare results obtained with the standard clinical characterization. Through the identification of various metabolites in the plasma (including free and conjugated bile acids and glycerophospholipids), and the integration of this information into predictive models, we were able to evaluate the extent of the hepatocellular or cholestatic phenotype and to assign a numeric value with the contribution of each specific DILI sub-phenotype into the patient's general condition. Additionally, our results showed that metabolomic analysis enabled the monitoring of DILI variability responses to the same drug, the transitions between sub-phenotypes during disease progression, and identified a spectrum of residual DILI metabolic features, which can be overlooked using standard clinical diagnosis during patient follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Herbal- and Dietary-Supplement-Induced Liver Injury: A Review of the Recent Literature.
- Author
-
Patel-Rodrigues, Palak A., Cundra, Lindsey, Alhaqqan, Dalal, Gildea, Daniel T., Woo, Stephanie M., and Lewis, James H.
- Subjects
MEDICAL protocols ,BIOLOGICAL models ,HEPATOTOXICOLOGY ,HERBAL medicine ,GREEN tea ,AYURVEDIC medicine ,PLANTS ,TURMERIC ,ALTERNATIVE medicine ,DIETARY supplements ,HORSE chestnut ,LEGUMES ,DISEASE complications - Abstract
Herbal-induced liver injury (HILI) continues to increase in prevalence each year due to the ongoing popularity of herbal supplements and complementary and alternative medicines. A detailed literature review of case reports and clinical studies published from March 2021 to March 2023 was performed. We discuss the epidemiology and diagnosis of HILI as well as the current and proposed laws and regulations. The 2021 ACG guidelines and 2022 AASLD practice guidelines for the diagnosis and management of drug and herbal-induced liver injury are discussed. We describe updates to previously reported etiologies of HILI such as ayurveda, ashwagandha, turmeric, kratom, green tea extract, and garcinia cambogia. Newly described supplements resulting in HILI, such as tinospora cordifolia, horse chestnut, alkaline water, and more, are described. We discuss newly and previously identified hepatoprotective herbal supplements as they have been reported in the study of animal models and human liver cells. This review suggests the need for ongoing research on the causes and mechanisms of HILI to ensure its proper diagnosis, prevention, and treatment in the future. The goal of this review is to provide novice and expert readers with knowledge regarding the possible etiologies of HILI and a general overview. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. The Hepatoprotective Effect of Glycyrrhiza glabra Roots Extract Against Amiodarone Induced Hepatotoxicity in Male Rats
- Author
-
Alzahraa Fatima Safa'a Fadhil, Yasir Mustafa Kamal, and Huda Jaber Waheed
- Subjects
Glycyrrhiza glabra ,Amiodarone ,DILI ,liver ,Pharmacy and materia medica ,RS1-441 - Abstract
Amiodarone (AMD), a powerful antidysrhythmic medication, can cause hepatotoxicity when used long-term or in high doses. It affects both mitochondrial and lysosomal function because of its lipophilic nature and accumulation in tissues. It also has direct production of ROS. Glycyrrhiza glabra is one of the medicinal plants that have been commonly used for thousands of years. It possesses anti-ulcer, anti-inflammatory and antioxidant properties. In this study, the antihepatotoxic effect of Gg was evaluated against AMD liver toxicity in rats model, thirty rats were taken and divided evenly into five groups given daily doses by gastric gavage oral tube for 3 weeks as follows: the 1st group acted as a control group given D.W., and the 2nd group received AMD at a dose of 300mg/kg for 2 weeks. 3rd, 4th, and 5th groups were pretreated with Gg in doses of 200, 400, and 800 mg, respectively, for one week, then along with AMD for 2 weeks. Hepatic damage, revealed by histology and the increased activities of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and serum phospholipase A2 (PLA2) was decreased in the AMD group. Gg extract significantly reduced the elevated AST and ALT levels caused by AMD intoxication, rendering PLA2 to its normal level. It also enhanced liver superoxide dismutase (SOD), glutathione (GSH), and malondialdehyde (MDA) levels. Gg extract markedly reverses the increased serum TNF levels induced by AMD; therefore, it may be considered a good hepatoprotective agent.
- Published
- 2024
- Full Text
- View/download PDF
30. CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment
- Author
-
Lucy Meunier, Eleonora De Martin, Bénédicte Delire, Wiliam Jacot, Severine Guiu, Amel Zahhaf, Dominique Larrey, and Yves Horsmans
- Subjects
DILI ,breast cancer ,hepatotoxicity ,Cyclin-dependent kinase inhibitors ,corticosteroids ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the cornerstone of systemic therapy for patients with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer. In the various therapeutic studies with CDK4/6 inhibitors, elevations in liver tests were more frequent than in the control groups. The mechanism of CDK4/6 inhibitor-induced liver toxicity is not well understood; moreover, natural history and appropriate management are poorly described. Methods: We conducted a retrospective study, collecting cases of CDK4/6 hepatitis from the REFHEPS (Réseau Francophone pour l’étude de l’HEpatotoxicité des Produits de Santé) database. Results: In this study, we report on 22 cases of hepatitis induced by CDK4/6 inhibitors (ribociclib, n = 19 and abemaciclib, n = 3). According to the CTCAE classification, all hepatitis cases were grade 3 or 4. Twelve (54.6%) patients had a liver biopsy showing acute centrilobular hepatitis with foci of necrosis and lymphocytic infiltrate. Nine (40.9%) patients were treated with corticosteroids for resolution of hepatitis. In three cases, another CDK4/6 inhibitor could be resumed after resolution of the hepatitis without recurrence. Conclusions: CDK4/6 inhibitor-induced hepatitis is poorly described in the literature but there are several arguments pointing out that these drugs should be included in the DI-ALH (drug-induced autoimmune-like hepatitis) category. Impact and implications: This study highlights the clinical significance and hepatotoxic risks of CDK4/6 inhibitors, like ribociclib and abemaciclib, in HR+/HER2-metastatic breast cancer treatment. It underscores the necessity for enhanced hepatic monitoring and tailored management strategies, including corticosteroid intervention for unresolved hepatitis post-withdrawal. These findings are crucial for oncologists, hepatologists, and patients, guiding therapeutic decisions and indicating careful liver function monitoring during therapy. The utility of corticosteroids in managing drug-induced hepatitis and the feasibility of resuming CDK4/6 inhibitor therapy post-recovery are notable practical outcomes. Nonetheless, the study's retrospective nature and limited case numbers introduce constraints, underscoring the need for further research to refine our understanding of CDK4/6 inhibitor-associated hepatotoxicity.
- Published
- 2024
- Full Text
- View/download PDF
31. The Morphological and Histopathological Liver Abnormalities Caused by Carbamazepine-Induced Injury in Female Albino Mice
- Author
-
Nawar R. Jaber and Nahla A. Al-Bakri
- Subjects
CBZ ,Liver ,DILI ,Mice ,hepatocytes ,Biotechnology ,TP248.13-248.65 ,Biology (General) ,QH301-705.5 - Abstract
Background: The adverse effects of drugs can damage various organs, especially the liver, leading to a hepatic injury known as hepatotoxicity. Drug-induced liver injury (DILI) is challenging nowadays because of the large number of different drugs used, one of the offending medications that cause DILI is carbamazepine (CBZ), since the liver has an array of functions including detoxification, it will deal with several damages caused by exposure to the drugs. Objective: investigate the effect of (CBZ) 20mg/kg/day on female mice liver after 14 and 30 days of treatment on morphological and histopathological levels. Materials and methods: 20mg/kg/day of CBZ was administered orally for (14) days to (10) female mice, another (10) mice were taking the same concentration for 30 days, and control groups were administered tap water. Results: The findings showed that CBZ can cause liver enlargement, changes in liver appearance, distortion in Glisson’s capsule, cytologic alterations, hepatocyte hypertrophy, ballooning degeneration, pyknosis, karyolysis, karyomegaly, sinusoids dilation, increase in the number and sizes of Kupffer cells, fibrosis, glycogen depletion, and cirrhosis. Conclusion: These findings have shown that carbamazepine (CBZ) can cause hepatotoxicity that can manifest into morphological and histopathological changes.
- Published
- 2024
- Full Text
- View/download PDF
32. Immune-mediated hepatitis: Basic concepts and treatment
- Author
-
J.A. Velarde-Ruiz Velasco, D.K. Tapia Calderón, S. Cerpa-Cruz, J.A. Velarde-Chávez, J.F. Uribe Martínez, E.S. García Jiménez, J.M. Aldana Ledesma, Á. Díaz-González, and J. Crespo
- Subjects
Hepatitis inmunomediada ,Inmunoterapia ,DILI ,Inhibidores de puntos de control inmunitario ,Tratamiento ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized advanced cancer management. Nevertheless, the generalized use of these medications has led to an increase in the incidence of adverse immune-mediated events and the liver is one of the most frequently affected organs.Liver involvement associated with the administration of immunotherapy is known as immune-mediated hepatitis (IMH), whose incidence and clinical characteristics have been described by different authors. It often presents as mild elevations of amino transferase levels, seen in routine blood tests, that spontaneously return to normal, but it can also manifest as severe transaminitis, possibly leading to the permanent discontinuation of treatment.The aim of the following review was to describe the most up-to-date concepts regarding the epidemiology, diagnosis, risk factors, and progression of IMH, as well as its incidence in different types of common cancers, including hepatocellular carcinoma. Treatment recommendations according to the most current guidelines are also provided. Resumen: La inmunoterapia con inhibidores de puntos de control inmunitario (ICP) ha revolucionado el manejo del cáncer avanzado, sin embargo, el uso generalizado de estos medicamentos ha llevado al aumento en la incidencia de eventos adversos inmunomediados, siendo el hígado uno de los órganos más frecuentemente afectados.La afectación hepática asociada con la administración de inmunoterapia se denomina hepatitis inmunomediada (HIM), cuya incidencia y características clínicas han sido descritas por distintos autores, frecuentemente se manifiesta como elevaciones leves en las aminotransferasas evidenciadas en la analítica de rutina que regresan a la normalidad de forma espontánea, aunque puede tratarse de una transaminasemia grave que lleve a la suspensión definitiva del tratamiento.El objetivo de la siguiente revisión fue describir los conceptos más actuales sobre la epidemiología, diagnóstico, factores de riesgo y evolución de la HIM, así como la incidencia de ésta en los diferentes tipos de cáncer más frecuentes incluyendo el carcinoma hepatocelular y algunas recomendaciones respecto al tratamiento de acuerdo con las guías más actuales.
- Published
- 2024
- Full Text
- View/download PDF
33. High-throughput screening of novel TFEB agonists in protecting against acetaminophen-induced liver injury in mice
- Author
-
Xiaojuan Chao, Mengwei Niu, Shaogui Wang, Xiaowen Ma, Xiao Yang, Hua Sun, Xujia Hu, Hua Wang, Li Zhang, Ruili Huang, Menghang Xia, Andrea Ballabio, Hartmut Jaeschke, Hong-Min Ni, and Wen-Xing Ding
- Subjects
Autophagy ,DILI ,Drug screening ,Hepatotoxicity ,Lysosome ,Mitochondria ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Macroautophagy (referred to as autophagy hereafter) is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles. Previous studies showed that autophagy protects against acetaminophen (APAP)-induced injury (AILI) via selective removal of damaged mitochondria and APAP protein adducts. The lysosome is a critical organelle sitting at the end stage of autophagy for autophagic degradation via fusion with autophagosomes. In the present study, we showed that transcription factor EB (TFEB), a master transcription factor for lysosomal biogenesis, was impaired by APAP resulting in decreased lysosomal biogenesis in mouse livers. Genetic loss-of and gain-of function of hepatic TFEB exacerbated or protected against AILI, respectively. Mechanistically, overexpression of TFEB increased clearance of APAP protein adducts and mitochondria biogenesis as well as SQSTM1/p62-dependent non-canonical nuclear factor erythroid 2-related factor 2 (NRF2) activation to protect against AILI. We also performed an unbiased cell-based imaging high-throughput chemical screening on TFEB and identified a group of TFEB agonists. Among these agonists, salinomycin, an anticoccidial and antibacterial agent, activated TFEB and protected against AILI in mice. In conclusion, genetic and pharmacological activating TFEB may be a promising approach for protecting against AILI.
- Published
- 2024
- Full Text
- View/download PDF
34. A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis—Can We Draw a Line?
- Author
-
Dorotea Božić, Ante Tonkić, Katarina Vukojevic, and Maja Radman
- Subjects
drug-induced autoimmune hepatitis ,AIH ,DILI ,acute hepatitis ,Medicine (General) ,R5-920 - Abstract
Idiosyncratic drug-induced liver injury (DILI) is an unpredictable reaction of individuals exposed to a certain drug, and drug-induced autoimmune hepatitis (DIAIH) presents a DILI phenotype that mimics idiopathic autoimmune hepatitis (AIH) when considering the clinical, biochemical, serological and histological parameters. We present a case report of a 48-year-old male who was hospitalized due to severe hepatocellular liver injury two months after self-treatment with a muscle-building dietary supplement based on arginine-alpha-ketoglutarate, L-citrulline, L tyrosine, creatine malate and beet extract. His immunology panel was positive with increased IgG levels, and radiologic methods showed no signs of chronic liver disease. He underwent corticosteroid treatment with adequate response. After therapy withdrawal, a clinical relapse occurred. Seven months after the initial presentation, liver MR suggested initial cirrhotic changes in the right liver lobe. A liver biopsy revealed abundant lymphoplasmacytic infiltrate with piecemeal necrosis and grade 2 fibrosis. He responded well to the corticosteroid treatment again, and was further treated with low-dose prednisone without additional relapses. Several years later, further management confirmed the presence of liver cirrhosis with no histological or biochemical signs of disease activity. DIAIH is a DILI phenotype that is difficult to distinguish from idiopathic AIH despite a wide armamentarium of diagnostic methods. It should always be considered among the differential diagnoses in patients presenting with hepatocellular liver injury.
- Published
- 2023
- Full Text
- View/download PDF
35. Regular Consumption of Green Tea as an Element of Diet Therapy in Drug-Induced Liver Injury (DILI)
- Author
-
Anna Winiarska-Mieczan, Karolina Jachimowicz-Rogowska, Małgorzata Kwiecień, Marta Borsuk-Stanulewicz, Agnieszka Tomczyk-Warunek, Ewa Stamirowska-Krzaczek, Cezary Purwin, Małgorzata Stryjecka, and Marzena Tomaszewska
- Subjects
DILI ,liver ,green tea ,catechin ,metabolism of drugs ,microbiota ,Nutrition. Foods and food supply ,TX341-641 - Abstract
The liver is a highly metabolically active organ, and one of the causes of its dysfunction is the damage caused by drugs and their metabolites as well as dietary supplements and herbal preparations. A common feature of such damage is drugs, which allows it to be defined as drug-induced liver injury (DILI). In this review, we analysed available research findings in the global literature regarding the effects of green tea and/or its phenolic compounds on liver function in the context of protective action during prolonged exposure to xenobiotics. We focused on the direct detoxifying action of epigallocatechin gallate (EGCG) in the liver, the impact of EGCG on gut microbiota, and the influence of microbiota on liver health. We used 127 scientific research publications published between 2014 and 2024. Improving the effectiveness of DILI detection is essential to enhance the safety of patients at risk of liver damage and to develop methods for assessing the potential hepatotoxicity of a drug during the research phase. Often, drugs cannot be eliminated, but appropriate nutrition can strengthen the body and liver, which may mitigate adverse changes resulting from DILI. Polyphenols are promising owing to their strong antioxidant and anti-inflammatory properties as well as their prebiotic effects. Notably, EGCG is found in green tea. The results of the studies presented by various authors are very promising, although not without uncertainties. Therefore, future research should focus on elucidating the therapeutic and preventive mechanisms of polyphenols in the context of liver health through the functioning of gut microbiota affecting overall health, with particular emphasis on epigenetic pathways.
- Published
- 2024
- Full Text
- View/download PDF
36. Lesión hepática inducida por medicamentos secundaria al consumo de esteroides androgénicos
- Author
-
Juan sebastian Theran Leon and Laura Yibeth Esteban Badillo
- Subjects
hepatitis ,hepatotoxicidad ,dili ,Medicine - Abstract
El uso de esteroides anabólicos de forma ilícita es un problema en aumento que se caracteriza por el desconocimiento sobre los potenciales efectos secundarios a estos productos. El uso ilegal de los mismos ha llevado a un infra diagnóstico de los eventos adversos, dentro de los mas frecuentes se ha encontrado la hepatotoxicidad. Se presenta el caso de un hombre adulto maduro deportista aficionado quien fue hospitalizado por ictericia y enfermedad hepática inducida por medicamentos en relación al uso de esteroides anabólicos en dosis elevadas. La prevención de la lesión hepática inducida por fármacos (DILI) implica educar a los pacientes que toman fármacos hepatotóxicos sobre su uso seguro, enseñar los signos y síntomas asociados con la lesión hepática, así como, la educación a la población vulnerable en prevenir la automedicación o el uso ilegal de estas sustancias.
- Published
- 2024
- Full Text
- View/download PDF
37. Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
- Author
-
Palmer, Melissa, Kleiner, David E., Goodman, Zachary, Brunt, Elizabeth, Avigan, Mark I., Regev, Arie, Hayashi, Paul H., Lewis, James H., Mehta, Ruby, Harrison, Stephen A., Siciliano, Massimo, McWherter, Charles A., Vuppalanchi, Raj, Behling, Cynthia, Miller, Veronica, Chalasani, Naga, and Sanyal, Arun J.
- Subjects
- *
LIVER biopsy , *LIVER injuries , *CLINICAL trials , *FATTY liver , *DRUG side effects , *NATALIZUMAB - Abstract
Summary: Background: Causality assessment of suspected drug‐induced liver injury (DILI) during metabolic dysfunction‐associated steatohepatitis (MASH) clinical trials can be challenging, and liver biopsies are not routinely performed as part of this evaluation. While the field is moving away from liver biopsy as a diagnostic and prognostic tool, information not identified by non‐invasive testing may be provided on histology. Aim: To address the appropriate utilisation of liver biopsy as part of DILI causality assessment in this setting. Methods: From 2020 to 2022, the Liver Forum convened a series of webinars on issues pertaining to liver biopsy during MASH trials. The Histology Working Group was formed to generate a series of consensus documents addressing these challenges. This manuscript focuses on liver biopsy as part of DILI causality assessment. Results: Expert opinion, guidance and recommendations on the role of liver biopsy as part of causality assessment of suspected DILI occurring during clinical trials for a drug(s) being developed for MASH are provided. Lessons learned from prior MASH programs are reviewed and gaps identified. Conclusions: Although there are no pathognomonic features, histologic evaluation of suspected DILI during MASH clinical trials may alter patient management, define the pattern and severity of injury, detect findings that favour a diagnosis of DILI versus MASH progression, identify prognostic features, characterise the clinicopathological phenotype of DILI, and/or define lesions that influence decisions about trial discontinuation and further development of the drug. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. High-throughput screening of novel TFEB agonists in protecting against acetaminophen-induced liver injury in mice.
- Author
-
Chao, Xiaojuan, Niu, Mengwei, Wang, Shaogui, Ma, Xiaowen, Yang, Xiao, Sun, Hua, Hu, Xujia, Wang, Hua, Zhang, Li, Huang, Ruili, Xia, Menghang, Ballabio, Andrea, Jaeschke, Hartmut, Ni, Hong-Min, and Ding, Wen-Xing
- Subjects
NUCLEAR factor E2 related factor ,DNA adducts ,HIGH throughput screening (Drug development) ,AUTOPHAGY ,MITOCHONDRIA formation ,LIVER injuries ,MITOCHONDRIAL proteins - Abstract
Macroautophagy (referred to as autophagy hereafter) is a major intracellular lysosomal degradation pathway that is responsible for the degradation of misfolded/damaged proteins and organelles. Previous studies showed that autophagy protects against acetaminophen (APAP)-induced injury (AILI) via selective removal of damaged mitochondria and APAP protein adducts. The lysosome is a critical organelle sitting at the end stage of autophagy for autophagic degradation via fusion with autophagosomes. In the present study, we showed that transcription factor EB (TFEB), a master transcription factor for lysosomal biogenesis, was impaired by APAP resulting in decreased lysosomal biogenesis in mouse livers. Genetic loss-of and gain-of function of hepatic TFEB exacerbated or protected against AILI, respectively. Mechanistically, overexpression of TFEB increased clearance of APAP protein adducts and mitochondria biogenesis as well as SQSTM1/p62-dependent non-canonical nuclear factor erythroid 2-related factor 2 (NRF2) activation to protect against AILI. We also performed an unbiased cell-based imaging high-throughput chemical screening on TFEB and identified a group of TFEB agonists. Among these agonists, salinomycin, an anticoccidial and antibacterial agent, activated TFEB and protected against AILI in mice. In conclusion, genetic and pharmacological activating TFEB may be a promising approach for protecting against AILI. Genetic and pharmacological activation of TFEB increases lysosomal biogenesis that promotes clearance of acetaminophen adducts resulting in protection against AILI. qHTS is a very useful platform to identify novel mTOR-dependent and independent TFEB agonists that may have translational therapeutic value for targeting drug-induced liver injury. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Unveiling the therapeutic promise of natural products in alleviating drug‐induced liver injury: Present advancements and future prospects.
- Author
-
Singh, Deepti, Khan, Mohammad Afsar, and Siddique, Hifzur R.
- Abstract
Drug‐induced liver injury (DILI) refers to adverse reactions to small chemical compounds, biological agents, and medical products. These reactions can manifest as acute or chronic damage to the liver. From 1997 to 2016, eight drugs, including troglitazone, nefazodone, and lumiracoxib, were removed from the market due to their liver‐damaging effects, which can cause diseases. We aimed to review the recent research on natural products and their bioactive components as hepatoprotective agents in mitigating DILI. Recent articles were fetched via searching the PubMed, PMC, Google Scholar, and Web of Science electronic databases from 2010 to January 2023 using relevant keywords such as "natural products," "acetaminophen," "antibiotics," "paracetamol," "DILI," "hepatoprotective," "drug‐induced liver injury," "liver failure," and "mitigation." The studies reveal that the antituberculosis drug (acetaminophen) is the most frequent cause of DILI, and natural products have been largely explored in alleviating acetaminophen‐induced liver injury. They exert significant hepatoprotective effects by preventing mitochondrial dysfunction and inflammation, inhibiting oxidative/nitrative stress, and macromolecular damage. Due to the bioavailability and dietary nature, using natural products alone or as an adjuvant with existing drugs is promising. To advance DILI management, it is crucial to conduct well‐designed randomized clinical trials to evaluate natural products' efficacy and develop new molecules clinically. However, natural products are a promising solution for remedying drug‐induced hepatotoxicity and lowering the risk of DILI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Ribociclib-induced liver injury: a case report.
- Author
-
Schaeffer, Sofia, Lutz, Christian, Dobbie, Michael, Terracciano, Luigi M., Matter, Matthias, Vosbeck, Jürg, Heim, Markus H., and Bernsmeier, Christine
- Subjects
HORMONE receptor positive breast cancer ,EPIDERMAL growth factor receptors ,LIVER enzymes ,LIVER injuries - Abstract
Background: Idiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US. Ribociclib is a potent Cyclin-dependent kinase 4 and 6 (CDK4/6)-inhibitor administered for advanced hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Previous reports have shown hepatotoxicity without liver necrosis related to ribociclib. Case presentation: A 41-year-old female patient with primary metastatic HRpositive, HER2-negative breast cancer developed liver enzyme elevation under treatment with ribociclib. Ribociclib was withdrawn 8 weeks after initiation due to liver enzyme elevation. A liver biopsy, performed due to further enzyme increase (peak ALT 2836 U/l), onset of jaundice (peak bilirubin 353 µmol/l) and coagulopathy (INR 1.8) two weeks later, revealed acute hepatitis with 30% parenchymal necrosis. Roussel Uclaf Causality Assessment Method (RUCAM) score was 7 points (probable). Under treatment with prednisone (60mg), initiated 2 weeks after drug withdrawal, and subsequently N-acetylcysteine (Prescott regimen) liver enzymes normalized within 8 weeks along with prednisone tapering. Conclusion: This case illustrates the development of a severe idiosyncratic hepatocellular pattern DILI grade 3 (International DILI Expert Working Group) induced by ribociclib. Routine liver enzyme testing during therapy, immediate hepatologic work-up and treatment interruption in case of liver enzyme elevation are highly recommended. Corticosteroid treatment should be considered in cases of severe necroinflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis—Can We Draw a Line?
- Author
-
Božić, Dorotea, Tonkić Jr., Ante, Vukojevic, Katarina, and Radman, Maja
- Subjects
- *
AUTOIMMUNE hepatitis , *DRUG side effects , *DISEASE relapse , *CIRRHOSIS of the liver , *LIVER diseases - Abstract
Idiosyncratic drug-induced liver injury (DILI) is an unpredictable reaction of individuals exposed to a certain drug, and drug-induced autoimmune hepatitis (DIAIH) presents a DILI phenotype that mimics idiopathic autoimmune hepatitis (AIH) when considering the clinical, biochemical, serological and histological parameters. We present a case report of a 48-year-old male who was hospitalized due to severe hepatocellular liver injury two months after self-treatment with a muscle-building dietary supplement based on arginine-alpha-ketoglutarate, L-citrulline, L tyrosine, creatine malate and beet extract. His immunology panel was positive with increased IgG levels, and radiologic methods showed no signs of chronic liver disease. He underwent corticosteroid treatment with adequate response. After therapy withdrawal, a clinical relapse occurred. Seven months after the initial presentation, liver MR suggested initial cirrhotic changes in the right liver lobe. A liver biopsy revealed abundant lymphoplasmacytic infiltrate with piecemeal necrosis and grade 2 fibrosis. He responded well to the corticosteroid treatment again, and was further treated with low-dose prednisone without additional relapses. Several years later, further management confirmed the presence of liver cirrhosis with no histological or biochemical signs of disease activity. DIAIH is a DILI phenotype that is difficult to distinguish from idiopathic AIH despite a wide armamentarium of diagnostic methods. It should always be considered among the differential diagnoses in patients presenting with hepatocellular liver injury. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
42. Differential Diagnosis: Hepatic Complications in Inborn Errors of Immunity.
- Author
-
Zinser, Emily, Tan, Ky-Lyn, Kim, Da-In S., O'Brien, Rachael, Winstanley, Alison, and Yong, Patrick F. K.
- Subjects
- *
AIDS-related opportunistic infections , *AUTOIMMUNE hepatitis , *HEMATOPOIETIC stem cells , *DIFFERENTIAL diagnosis , *STEM cell transplantation , *IMMUNITY , *LIVER histology - Abstract
Inborn errors of immunity (IEIs) are a heterogeneous group of diverse clinical and genetic phenotypes that have an estimated combined prevalence as high as 1/1000. Increased risk of frequent, severe, or opportunistic infections is a common feature of IEIs, but there are also diverse immune-mediated, non-infective complications that are associated with significant morbidity and mortality. As patient survival increases, these are becoming more apparent within the liver. Hepatic involvement of IEIs may not only manifest as infections, but also nodular regenerative hyperplasia, granulomatous disease, autoimmune hepatitis and malignancy. As therapeutic options for patients are expanding, with both pharmaceutical treatments as well as haematopoietic stem cell transplant (HSCT), iatrogenic liver injury is increasingly common and important to identify. This review article summarises the spectrum of hepatic complications seen in IEIs, and highlights the challenges of management within this patient cohort, where immunosuppression is poorly tolerated. Early recognition and prompt diagnosis of potential hepatic complications is therefore crucial in ensuring potentially reversible causes are treated, but significant uncertainty remains regarding best practice for many features of immune dysregulation with limited high-quality evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
43. HLA-targeted sequencing reveals the pathogenic role of HLA-B*15: 02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature.
- Author
-
Jin-Mao Liao, Yan Zhan, Zheng Zhang, Jia-Jia Cui, and Ji-Ye Yin
- Subjects
LITERATURE reviews ,LIVER failure ,DRUG side effects ,BLOOD coagulation ,LIVER injuries - Abstract
Drug-induced liver injury (DILI) is one of the serious adverse drug reactions (ADRs), which belongs to immune-mediated adverse drug reactions (IM-ADRs). As an essential health drug, albendazole has rarely been reported to cause serious liver damage. A young man in his 30 s developed severe jaundice, abnormal transaminases, and poor blood coagulation mechanism after taking albendazole, and eventually developed into severe liver failure. The patient was found heterozygous of HLA-B*15:02 and HLA-B*13:01 through HLA-targeted sequencing, which may have a pathogenic role in the disease. This case report summarizes his presentation, treatment, and prognosis. A useful summary of the diagnosis and associated genetic variant information is provided. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
44. Comparative analysis of classification techniques for topic-based biomedical literature categorisation.
- Author
-
Stepanov, Ihor, Ivasiuk, Arsentii, Yavorskyi, Oleksandr, and Frolova, Alina
- Subjects
TRANSFORMER models ,DRUG registration ,COMPARATIVE studies ,CLASSIFICATION ,INFORMATION resources ,HOPFIELD networks ,INFORMATION theory ,IDENTIFICATION - Abstract
Introduction: Scientific articles serve as vital sources of biomedical information, but with the yearly growth in publication volume, processing such vast amounts of information has become increasingly challenging. This difficulty is particularly pronounced when it requires the expertise of highly qualified professionals. Our research focused on the domain-specific articles classification to determine whether they contain information about drug-induced liver injury (DILI). DILI is a clinically significant condition and one of the reasons for drug registration failures. The rapid and accurate identification of drugs that may cause such conditions can prevent side effects in millions of patients. Methods: Developing a text classification method can help regulators, such as the FDA, much faster at a massive scale identify facts of potential DILI of concrete drugs. In our study, we compared several text classification methodologies, including transformers, LSTMs, information theory, and statistics-based methods. We devised a simple and interpretable text classification method that is as fast as Naïve Bayes while delivering superior performance for topic-oriented text categorisation. Moreover, we revisited techniques and methodologies to handle the imbalance of the data. Results: Transformers achieve the best results in cases if the distribution of classes and semantics of test data matches the training set. But in cases of imbalanced data, simple statistical-information theory-based models can surpass complex transformers, bringing more interpretable results that are so important for the biomedical domain. As our results show, neural networks can achieve better results if they are pre-trained on domain-specific data, and the loss function was designed to reflect the class distribution. Discussion: Overall, transformers are powerful architecture, however, in certain cases, such as topic classification, its usage can be redundant and simple statistical approaches can achieve compatible results while being much faster and explainable. However, we see potential in combining results from both worlds. Development of new neural network architectures, loss functions and training procedures that bring stability to unbalanced data is a promising topic of development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
45. Cyclopia intermedia E. Mey protects against ROS-induced liver injury in HepG2/C3A cells.
- Author
-
Reddy, Shanika, Rashed, Khaled, Marnewick, Jeanine L., Rautenbach, Fanie G., Koekemoer, Trevor, and van de Venter, Maryna
- Subjects
- *
LIVER injuries , *STEREOLOGY , *SULFHYDRYL group , *FLUORESCENCE microscopy , *OXIDANT status - Abstract
• First study investigating scavenging activities of honeybush extract on human erythrocytes in the CAPe assay. • First study to assess antioxidant capacity of honeybush extract on HepG2/C3A cells using fluorescence microscopy. • This study validates therapeutic possibilities of honeybush extract for ROS-induced liver injuries. Drug-induced liver injury (DILI) represents a significant clinical problem for which no standard treatment currently exists. Most DILI mechanisms center on oxidative stress resulting from glutathione depletion, excessive ROS production, and subsequent cell death. Flavonoid-rich Cyclopia intermedia E. Mey (honeybush) is a commercially important African herbal tea and is traditionally promoted as a restorative treatment. Cytotoxicity evaluation of a fermented C. intermedia extract in C3A hepatocytes confirmed the absence of toxicity up to 200 µg/mL using quantitative fluorescence microscopy with Hoechst 33342-PI dual-labeling. DPPH, NO scavenging, and ORAC assays established a strong antioxidant potential. Antioxidant bioavailability, assessed using the CAPe assay, indicated significant uptake at 100 µg/mL (p < 0.005). C. intermedia extract decreased TBHP-induced oxidative stress in C3A cells and attenuated TBHP-induced changes in thiol group levels at 200 µg/mL (p < 0.005) as confirmed by CellROX® Orange and ThiolTracker™ Violet staining, respectively. Apoptotic cell death was significantly reduced by the extract from 50 µg/mL (p < 0.005) as determined by Annexin-V FITC staining. These results suggest that C. intermedia can function as a hepatoprotectant and has potential as a treatment against DILI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Acute Endoplasmic Reticulum Stress Suppresses Hepatic Gluconeogenesis by Stimulating MAPK Phosphatase 3 Degradation.
- Author
-
Huang, Xiaohua, Zhu, Heng, Lu, Wei, Cao, Lei, Fang, Zhengfeng, Che, Lianqiang, Lin, Yan, Xu, Shengyu, Zhuo, Yong, Hua, Lun, Jiang, Xuemei, Sun, Mengmeng, Wu, De, and Feng, Bin
- Subjects
- *
MITOGEN-activated protein kinase phosphatases , *ENDOPLASMIC reticulum , *GLUCONEOGENESIS , *BLOOD sugar , *HEAT shock proteins , *INSULIN - Abstract
Drug-induced liver injury (DILI) is a widespread and harmful disease, and is closely linked to acute endoplasmic reticulum (ER) stress. Previous reports have shown that acute ER stress can suppress hepatic gluconeogenesis and even leads to hypoglycemia. However, the mechanism is still unclear. MAPK phosphatase 3 (MKP-3) is a positive regulator for gluconeogenesis. Thus, this study was conducted to investigate the role of MKP-3 in the suppression of gluconeogenesis by acute ER stress, as well as the regulatory role of acute ER stress on the expression of MKP-3. Results showed that acute ER stress induced by tunicamycin significantly suppressed gluconeogenesis in both hepatocytes and mouse liver, reduced glucose production level in hepatocytes, and decreased fasting blood glucose level in mice. Additionally, the protein level of MKP-3 was reduced by acute ER stress in both hepatocytes and mouse liver. Mkp-3 deficiency eliminated the inhibitory effect of acute ER stress on gluconeogenesis in hepatocytes. Moreover, the reduction effect of acute ER stress on blood glucose level and hepatic glucose 6-phosphatase (G6pc) expression was not observed in the liver-specific Mkp-3 knockout mice. Furthermore, activation of protein kinase R-like ER kinase (PERK) decreased the MKP-3 protein level, while inactivation of PERK abolished the reduction effect of acute ER stress on the MKP-3 protein level in hepatocytes. Taken together, our study suggested that acute ER stress could suppress hepatic gluconeogenesis by stimulating MKP-3 degradation via PERK, at least partially. Thus, MKP-3 might be a therapeutic target for DILI-related hypoglycemia. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update
- Author
-
Tom Boyles, Rebecca H. Berhanu, Neliswa Gogela, Hannah Gunter, Tamsin Lovelock, Ndiviwe Mphothulo, Arifa Parker, Helena Rabie, Lauren Richards, Phumla Sinxadi, Camilla Wattrus, and Mahomed-Yunus Moosa
- Subjects
drug-induced liver injury ,dili ,liver injury ,liver ,anti-tuberculous therapy ,anti-tubercolous drugs ,Public aspects of medicine ,RA1-1270 ,Infectious and parasitic diseases ,RC109-216 - Abstract
No abstract available.
- Published
- 2024
- Full Text
- View/download PDF
48. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
- Author
-
Bocci, Giovanni, Oprea, Tudor I, and Benet, Leslie Z
- Subjects
Animals ,Biopharmaceutics ,Chemical and Drug Induced Liver Injury ,Permeability ,Pharmaceutical Preparations ,Solubility ,BDDCS ,BCS ,DILI ,dose number ,extent of metabolism ,food effects ,solubility ,Pharmacology and Pharmaceutical Sciences ,Pharmacology & Pharmacy - Abstract
The Biopharmaceutics Drug Disposition Classification system (BDDCS) is a four-class approach based on water solubility and extent of metabolism/permeability rate. Based on the BDDCS class to which a drug is assigned, it is possible to predict the role of metabolic enzymes and transporters on the drug disposition of a new molecular entity (NME) prior to its administration to animals or humans. Here, we report a total of 1475 drugs and active metabolites to which the BDDCS is applied. Of these, 379 are new entries, and 1096 are revisions of former classification studies with the addition of references for the approved maximum dose strength, extent of the systemically available drug excreted unchanged in the urine, and lowest solubility over the pH range 1.0-6.8 when such information is available in the literature. We detail revised class assignments of previously misclassified drugs and the literature analyses to classify new drugs. We review the process of solubility assessment for NMEs prior to drug dosing in humans and approved dose classification, as well as the comparison of Biopharmaceutics Classification System (BCS) versus BDDCS assignment. We detail the uses of BDDCS in predicting, prior to dosing animals or humans, disposition characteristics, potential brain penetration, food effect, and drug-induced liver injury (DILI) potential. This work provides an update on the current status of the BDDCS and its uses in the drug development process.
- Published
- 2022
49. Single-cell metabolic profiling reveals subgroups of primary human hepatocytes with heterogeneous responses to drug challenge
- Author
-
Eva Sanchez-Quant, Maria Lucia Richter, Maria Colomé-Tatché, and Celia Pilar Martinez-Jimenez
- Subjects
Primary human hepatocytes ,Drug metabolism ,Single-cell transcriptomics ,Hepatic steatosis ,NAFLD ,DILI ,Biology (General) ,QH301-705.5 ,Genetics ,QH426-470 - Abstract
Abstract Background Xenobiotics are primarily metabolized by hepatocytes in the liver, and primary human hepatocytes are the gold standard model for the assessment of drug efficacy, safety, and toxicity in the early phases of drug development. Recent advances in single-cell genomics demonstrate liver zonation and ploidy as main drivers of cellular heterogeneity. However, little is known about the impact of hepatocyte specialization on liver function upon metabolic challenge, including hepatic metabolism, detoxification, and protein synthesis. Results Here, we investigate the metabolic capacity of individual human hepatocytes in vitro. We assess how chronic accumulation of lipids enhances cellular heterogeneity and impairs the metabolisms of drugs. Using a phenotyping five-probe cocktail, we identify four functional subgroups of hepatocytes responding differently to drug challenge and fatty acid accumulation. These four subgroups display differential gene expression profiles upon cocktail treatment and xenobiotic metabolism-related specialization. Notably, intracellular fat accumulation leads to increased transcriptional variability and diminishes the drug-related metabolic capacity of hepatocytes. Conclusions Our results demonstrate that, upon a metabolic challenge such as exposure to drugs or intracellular fat accumulation, hepatocyte subgroups display different and heterogeneous transcriptional responses.
- Published
- 2023
- Full Text
- View/download PDF
50. A diagnostic challenge: Life-threatening drug reaction with eosinophilia and systemic symptoms in the setting of a SARS-CoV-2 and human herpesvirus-6 reactivation in a patient with severe hepatic injury on bupropion
- Author
-
Djoni Elkady, BS, Chiamaka L. Okorie, BS, Blanca Estupiñan, MD, Mitul B. Modi, MD, Scott J. Cotler, MD, and Eden Lake, MD
- Subjects
bupropion ,COVID ,DILI ,DRESS ,drug-induced ,drug reaction ,Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.